Amicus Therapeutics (NASDAQ:FOLD) Insider David Michael Clark Sells 25,643 Shares of Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) insider David Michael Clark sold 25,643 shares of the business’s stock in a transaction dated Tuesday, November 4th. The shares were sold at an average price of $9.51, for a total transaction of $243,864.93. Following the completion of the sale, the insider directly owned 322,618 shares of the company’s stock, valued at approximately $3,068,097.18. The trade was a 7.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

Amicus Therapeutics Stock Up 2.2%

FOLD stock opened at $9.19 on Thursday. The stock has a market capitalization of $2.83 billion, a P/E ratio of -76.58 and a beta of 0.66. The company has a current ratio of 3.21, a quick ratio of 2.29 and a debt-to-equity ratio of 1.92. Amicus Therapeutics, Inc. has a 12 month low of $5.51 and a 12 month high of $12.65. The firm has a 50-day moving average price of $8.25 and a 200-day moving average price of $7.06.

Amicus Therapeutics (NASDAQ:FOLD) last posted its earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The firm had revenue of $169.06 million during the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a negative net margin of 6.67% and a negative return on equity of 5.07%. The business’s revenue for the quarter was up 19.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.10 earnings per share. Amicus Therapeutics has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have recently issued reports on FOLD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Amicus Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating in a research report on Sunday, October 26th. Zacks Research raised shares of Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 6th. Morgan Stanley raised shares of Amicus Therapeutics from an “equal weight” rating to an “overweight” rating in a research report on Thursday, July 17th. Finally, Needham & Company LLC raised shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 target price for the company in a research report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $16.13.

Institutional Trading of Amicus Therapeutics

Several large investors have recently modified their holdings of the stock. Envestnet Asset Management Inc. grew its position in shares of Amicus Therapeutics by 9.9% during the 3rd quarter. Envestnet Asset Management Inc. now owns 70,600 shares of the biopharmaceutical company’s stock worth $556,000 after buying an additional 6,344 shares during the period. Allianz Asset Management GmbH grew its position in shares of Amicus Therapeutics by 0.3% during the 3rd quarter. Allianz Asset Management GmbH now owns 389,109 shares of the biopharmaceutical company’s stock worth $3,066,000 after buying an additional 1,333 shares during the period. State of Wyoming grew its position in shares of Amicus Therapeutics by 1,034.9% during the 3rd quarter. State of Wyoming now owns 10,078 shares of the biopharmaceutical company’s stock worth $79,000 after buying an additional 9,190 shares during the period. Principal Financial Group Inc. grew its position in shares of Amicus Therapeutics by 1,229.5% during the 3rd quarter. Principal Financial Group Inc. now owns 263,325 shares of the biopharmaceutical company’s stock worth $2,075,000 after buying an additional 243,519 shares during the period. Finally, AlphaQuest LLC grew its position in shares of Amicus Therapeutics by 34.1% during the 3rd quarter. AlphaQuest LLC now owns 108,874 shares of the biopharmaceutical company’s stock worth $858,000 after buying an additional 27,698 shares during the period.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.